Management of Aggressive Medullary Thyroid Cancer Abstract #2186

Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the C cells of thyroid gland characterized by significant morbidity.
Aim(s): We aimed to describe clinical management of our series of patients affected by aggressive MTC with metastatic disease.
Materials and methods: In the last five years, we followed-up five patients affected by aggressive MTC.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Chiara Bima

To read results and conclusion, please login ...

Further abstracts you may be interested in

#48 Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maralyn R Druce
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#160 The role of T-type calcium channels in medullary thyroid carcinoma (MTC): T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a human MTC cell line
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5-10% of thyroid cancers. In the case of tumors limited to the thyroid gland, the prognosis is generally favorable, whereas 5-year survival averages only 40% in patients with metastatic disease. In these patients, conventional chemotherapy only occasionally leads to a complete response and partial responses are observed in less than 30% of the cases. Therefore, intense efforts are currently directed toward the identification of new druggable targets for the treatment of this devastating disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Rosario Pivonello
#201 Comparison of 18F-DOPA, 68Ga-Somatostatin Analogues and 18F-FDG PET-CT in Patients with Recurrent Medullary Thyroid Carcinoma
Introduction: Various PET tracers have been proposed for detection of recurrent disease in medullary thyroid carcinoma (MTC). No data have been reported comparing 18F-DOPA and 68Ga-somatostin analogues (SA) in MTC.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Giorgio Treglia